Ovitrop Injection
Urofollitropin
50IU
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Ovitrop Injection is used for:
Female infertility, Hypogonadotrophic hypogonadism
Adult Dose
Injection
Polycystic ovarian syndrome; Female infertility
Adult: Initially, 150 IU daily SC/IM for the first 5 days. Adjust subsequent dosing based on clinical monitoring (e.g. serum oestradiol levels and vaginal ultrasound). Dose adjustments should not be made more frequently than once every 2 days and be ?75-150 units per adjustment. Max dose: 450 units daily and max course of treatment: 12 days. Stop treatment when adequate response obtained as determined by oestrogen monitoring or ultrasonic visualisation of follicles. A single dose of chorionic gonadotrophin 5000 to 10 000 units is given to induce ovulation after 1-2 days. Urofollitropin treatment may be tried again in future cycles.
Injection
In vitro fertilisation procedures or other assisted conception techniques
Adult: In conjunction with other agents: 150-225 units of FSH daily SC/IM from day 2 or 3 of menstrual cycle. Alternatively, begin therapy with clomifene citrate and continue with urofollitropin; or urofollitropin may be given after gonadorelin analogue is given to suppress gonadotrophin release. Continue treatment until an adequate response is obtained and admin 5000 to 10 000 units of chorionic gonadotrophin 1-2 days after final injection of urofollitropin. Oocyte retrieval is performed 34-35 hr later.
Injection
Male infertility
Adult: In conjunction with chorionic gonadotrophin, 150 units of FSH SC/IM 3 times a wk, continue for at least 4 mth.
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Contra Indications
Pregnancy, ovarian cysts or enlargement not due to polycystic ovary syndrome, primary ovarian failure, organic intracranial lesion e.g. pituitary tumour, uncontrolled thyroid and adrenal dysfunction, presence of any cause of infertility other than anovulation, abnormal bleeding of undetermined origin.
Precautions
May result in multiple pregnancies. Abnormal genital bleeding, hormone sensitive malignancies, ovarian cysts not caused by polycystic ovary syndrome. Exclude and treat other causes of infertility e.g. pituitary or hypothalamic lesions, adrenal or thyroid disorders and hyperprolactinaemia.
Pregnancy-Lactation
Interactions
Increased risk of ovarian hyperstimulation syndrome with drugs with luteinising hormone activity.
Adverse Effects
Side effects of Urofollitropin :
>10%
Headache (11.1%), OHSS (11.1%; severe pelvic pain, N/V, weight gain)
Frequency Not Defined
Nausea, vomiting, joint pain, ovarian hyperstimulation syndrome, adnexal torsion, mild to moderate ovarian enlargement, abdominal pain, ovarian cysts, local reaction at inj site, headaches, haemoperitoneum, benign and malignant ovarian neoplasms, ascites, pleural effusion, hypovolaemia, thromboembolic disorders. Weight gain, acne and gynaecomastia in men.
Potentially Fatal: Ovarian cysts rupture, intraperitoneal haemorrhage.
Mechanism of Action
Urofollitropin, a gonadotrophin obtained from postmenopausal women's urine, possesses follicle-stimulating hormone (FSH) activity but almost no luteinising activity. Admin for 7-12 days results in follicular growth and maturation in females. When sufficient follicular maturation has occurred, human chorionic gonadotrophin should be given to induce ovulation.
Note
Ovitrop 50IU Injection manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Urofollitropin. Ovitrop is availble in Nepal.
Farmaco Nepal drug index information on Ovitrop Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.